Effects of adenosine on functions of polymorphonuclear leukocytes from patients with septic shock

Ines Kaufmann1, Alwin Hoelzl, Florian Schliephake

  • 1Department of Anesthesiology, Klinikum Grosshadern, Munich, Germany.

Shock (Augusta, Ga.)
|December 19, 2006
PubMed

Insights

Adenosine selectively reduces harmful hydrogen peroxide production by immune cells in septic shock patients without impairing bacterial defense. This suggests adenosine or A2A agonists could treat sepsis-related tissue damage.

Area of Science:

  • Immunology
  • Pharmacology
  • Critical Care Medicine

Background:

  • Polymorphonuclear leukocytes (PMNs) are crucial for fighting bacteria but can cause tissue damage during inflammation.
  • Adenosine, a metabolite produced during inflammation, may modulate adverse PMN reactions, but its selective effects in sepsis are unknown.
  • Developing drugs to attenuate tissue-toxic PMN responses without compromising antibacterial mechanisms is a critical medical need.

Purpose of the Study:

  • To investigate the ex vivo effects of adenosine on PMN functions in patients with septic shock (SS) compared to healthy volunteers (HV).
  • To determine if adenosine can selectively downregulate the tissue-toxic hydrogen peroxide (H2O2) production by PMNs in septic shock.
  • To assess the impact of adenosine on PMN adhesion, phagocytosis, and H2O2 production stimulated by various inflammatory mediators.

Main Methods:

  • Prospective clinical study involving 33 SS patients and 33 HV.
  • PMNs were primed with tumor necrosis factor-alpha (TNF-alpha) and stimulated with N-formyl methionyl-leucyl-phenylalanine (fMLP) to measure H2O2 production.
  • PMN functions (adhesion, phagocytosis, H2O2 production) were assessed using opsonized zymosan particles, with and without adenosine or A2A agonists.

Main Results:

  • PMNs from SS patients exhibited significantly enhanced tissue-toxic H2O2 production compared to HV.
  • Adenosine dose-dependently reduced H2O2 production in both groups, with a lower inhibitory potency in SS patients (IC50: 114 nmol/L vs. 25 nmol/L in HV).
  • Adenosine did not affect PMN adhesion or phagocytosis of zymosan particles, and these effects were confirmed using a selective A2A agonist (CGS21680).

Conclusions:

  • Adenosine selectively inhibits potentially tissue-toxic H2O2 production by PMNs in response to soluble inflammatory mediators in septic shock.
  • The reduced sensitivity to adenosine in septic shock PMNs is compensated by increased endogenous adenosine plasma concentrations.
  • Adenosine or A2A agonists represent a potential therapeutic strategy to mitigate tissue injury in septic shock without compromising essential immune functions.

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...